Loading...
Ons wil graag hê dat jy deel word van ons gemeenskap. Sluit aan by ons Discord om met ons en ander lede te skakel!
- Ticker
- BSLN.SW
- Price
- 41.35
- Stock movement down
- -0.25 (-0.60%)
- Company name
- Basilea Pharmaceutica AG
- Exchange
- (SW ,
- Currency
- CHF )
- Sector
- Healthcare >Biotechnology
- Markkapitalisasie
- 501.21M
- Ondernemingswaarde
- 610.12M
- Prys/Verkope
- 2.14
- Prys/Boek
- 29.86
- Dividendopbrengs
- -
- Dividendgroei
- -
- Groei jare
- -
- FCF uitbetaling
- 117.97%
- Agterlopende P/E
- 16.07
- Volgende P/E
- 11.55
- PEG
- -
- EPS groei
- -
- 1 jaar opbrengs
- 17.81%
- 3 jaar opbrengs
- -0.60%
- 5 jaar opbrengs
- -3.16%
- 10 jaar opbrengs
- -7.79%
Laaste opgedateer: 2024-12-21
DIVIDENDE
BSLN.SW betaal nie dividende nie of geen data is ontvang nie
WAARDERING
Waarderingsverhoudings
Loading...
Waarderingsverhoudings gegewens
| Agterlopende P/E | 16.07 |
| Prys tot OCF | 15.58 |
| Prys tot FCF | 16.35 |
| Prys tot EBITDA | 14.77 |
| EV tot EBITDA | 17.98 |
Waardering (Verkope/Boekwaarde)
Loading...
Waardering (Verkope/Boekwaarde) gegewens
| Prys tot verkope | 2.14 |
| Prys tot Boekwaarde | 29.86 |
| EV tot verkope | 2.61 |
FINANSIËLE
Per aandeel
Loading...
Per aandeel gegewens
| Huidige aandeeltelling | 12.12M |
| EPS (TTM) | 2.26 |
| FCF per aandeel (TTM) | 2.22 |
Inkomstestaat
Loading...
Inkomstestaat gegewens
| Inkomste (TTM) | 233.93M |
| Bruto wins (TTM) | 155.42M |
| Bedryfsinkomste (TTM) | 28.46M |
| Netto inkomste (TTM) | 31.19M |
| EPS (TTM) | 2.26 |
| EPS (1j vorentoe) | 3.58 |
Marges
Loading...
Marges gegewens
| Bruto marge (TTM) | 66.44% |
| Bedryfsmarge (TTM) | 12.17% |
| Winsgrens (TTM) | 13.33% |
Balansstaat
Loading...
Skep asseblief 'n gratis rekening of meld aan om toegang tot hierdie grafiek te kry
Balansstaat gegewens
| Kontant | 62.96M |
| Netto debiteure | 28.08M |
| Totale bedryfsbates | 155.01M |
| Klandisiewaarde | 0.00 |
| Ontasbare bates | 473.00K |
| Eiendom, aanleg en toerusting | 0.00 |
| Totale bates | 188.66M |
| Rekeninge betaalbaar | 11.47M |
| Kort/huidige langtermynskuld | 112.45M |
| Totale bedryfslaste | 37.78M |
| Totale laste | 171.88M |
| Aandeelhouersbelang | 16.79M |
| Netto tasbare bates | 0.00 |
Kontantvloei
Loading...
Skep asseblief 'n gratis rekening of meld aan om toegang tot hierdie grafiek te kry
Kontantvloei gegewens
| Bedryfskontantvloei (TTM) | 32.16M |
| Kapitale uitgawes (TTM) | 1.50M |
| Vrye kontantvloei (TTM) | 30.66M |
| Dividende betaal (TTM) | 36.17M |
Finansiële opbrengste
Loading...
Skep asseblief 'n gratis rekening of meld aan om toegang tot hierdie grafiek te kry
Finansiële opbrengste gegewens
| Opbrengs op ekwiteit | 185.80% |
| Opbrengs op bates | 16.53% |
| Opbrengs op belegde kapitaal | 165.47% |
| Kontant opbrengs op belegde kapitaal | 162.69% |
AANDELE INLIGTING
Aandele grafiek
Loading...
Aandele prys data
| Open | 41.60 |
| Daaglikse hoog | 41.60 |
| Daaglikse laag | 40.60 |
| Daaglikse volume | 21K |
| Hoogtepunt van alle tye | 282.25 |
| 1j analiseraaming | 81.62 |
| Beta | 0.74 |
| EPS (TTM) | 2.26 |
| Dividend per aandeel | - |
| Ex-dividend datum | 11 Apr 2013 |
| Volgende verdienste datum | 11 Feb 2025 |
Afwaartse potensiaal
Loading...
Afwaartse potensiaal gegewens
| BSLN.SW | S&P500 | |
| Huidige prysdaling vanaf die hoogste punt van alle tye | -85.35% | -2.74% |
| Hoogste prysdaling | -89.76% | -56.47% |
| Datum van hoogste daling | 23 Nov 2011 | 9 Mar 2009 |
| Gemiddelde daling vanaf hoogtepunt | -63.49% | -11.13% |
| Gemiddelde tyd tot nuwe hoogtepunt | 71 days | 12 days |
| Maksimum tyd tot nuwe hoogtepunt | 4457 days | 1805 days |
MAATSKAPPY BESONDERHEDE
Markkapitalisasie
501.21M
Markkapitalisasie kategorie
Small-cap
Beskrywing
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as offers treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. Further, it offers Fosmanogepix, an antifungal drug for the treatment of Candidemia which in Phase II clinical trials. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.
Werknemers
156
Webwerf
Beleggerverhoudings
-
SEC lêers
CEO
Land
Switzerland
Stad
Aandele tipe
-
CCC status
-
Dividendfrekwensie
-
GEBEURE EN AANBIEDINGS
GebeureAanbiedings
Loading...
VERSTAAN DIE BESIGHEID
Loading...
MAATSKAPPY NUUS
Alle nuusPersvrystellings
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, December 16, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting...
16 Desember 2024
Allschwil, Switzerland, September 24, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacteri...
24 September 2024
Initial funding of USD 29 million to support development of Basilea’s clinical stage first-in-class antifungals, fosmanogepix and BAL2062Multi-year Other Transaction Agreement (OTA) allows for potenti...
19 September 2024
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, September 6, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting...
6 September 2024
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, August 27, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting t...
27 Augustus 2024
Allschwil, Switzerland, August 21, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial ...
21 Augustus 2024
Basilea Pharmaceutica (BPMUF) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed...
20 Augustus 2024
Continued success of Cresemba® with 16.6% growth of royalties to CHF 42.8 million Operating result of CHF 9.3 million, net profit of CHF 20.7 millionTotal revenue guidance increased by 7% to CHF ~196 ...
13 Augustus 2024
Allschwil, Switzerland, June 20, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial an...
20 Junie 2024
If you are looking for stocks that are well positioned to maintain their recent uptrend, Basilea Pharmaceutica (BPMUF) could be a great choice. It is one of the several stocks that passed through our ...
21 Mei 2024
Volgende bladsy